Inozyme Pharma Inc. (INZY) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for INZY in the last 30 days. The most recent was published Jul 17, 2025.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Latest news

25 items

INZY FAQ

8 questions
  • What does Inozyme Pharma Inc. do?
    Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
  • What is the latest news on INZY?
    Quantisnow has not tracked any new filings, ratings or press releases for INZY in the last 30 days. The most recent wire item was published on July 17, 2025.
  • Where does INZY stock trade?
    Inozyme Pharma Inc. (INZY) is listed on NASDAQ.
  • What sector and industry is INZY in?
    Inozyme Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Inozyme Pharma Inc. go public?
    Inozyme Pharma Inc. (INZY) completed its IPO in 2020.
  • What are analysts saying about INZY?
    Across the last 8 analyst actions on Inozyme Pharma Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Raymond James: Outperform with a $26.00 price target on 2024-12-12.
  • What companies are similar to INZY?
    Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare INZY side-by-side with any of them on Quantisnow.
  • How can I track INZY on Quantisnow?
    Quantisnow aggregates Inozyme Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INZY to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change